David Ashley

Overview:

Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.

In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.

Positions:

Rory David Deutsch Distinguished Professor of Neuro-Oncology

Neurosurgery
School of Medicine

Professor of Neurosurgery

Neurosurgery
School of Medicine

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Professor in Pathology

Pathology
School of Medicine

Professor in Pediatrics

Pediatrics, Hematology-Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

F.R.A.C.P. 1993

Royal Australasian College of Physicians (Australia)

M.B.B.S. 1994

University of Melbourne (Australia)

Ph.D. 1998

University of Melbourne (Australia)

Grants:

LGG-14C03: A Phase III study comparing two carboplatin containing regimens for children and young adults with previously untreated low grade glioma

Administered By
Duke Cancer Institute
Awarded By
Ann & Robert H Lurie Children's Hospital of Chicago
Role
Principal Investigator
Start Date
End Date

SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Administered By
Pediatrics, Hematology-Oncology
Awarded By
St. Jude Children's Research Hospital
Role
Principal Investigator
Start Date
End Date

NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEMPRIMITIVE NEURO-ECTODERMAL TUMORS:CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WI

Administered By
Duke Cancer Institute
Awarded By
Research Institute at Nationwide Children's Hospital
Role
Principal Investigator
Start Date
End Date

Collaborative Network for Neuroooncology Clinical Trials (CONNECT)

Administered By
Duke Cancer Institute
Awarded By
Cincinnati Children's Hospital Medical Center
Role
Principal Investigator
Start Date
End Date

A Phase II study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours (ATRT)

Administered By
Duke Cancer Institute
Awarded By
Australian and New Zealand Children's Haematology/Oncology Group
Role
Principal Investigator
Start Date
End Date

Publications:

A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS

Authors
Wood, P; Desai, J; Waldeck, K; Cain, J; Gottardo, N; Strong, R; Kinross, K; Carr, M; Jones, J; Wong, L; Ziegler, D; Hansford, J; Michael, M; Ashley, D
URI
https://scholars.duke.edu/individual/pub1473625
Source
wos-lite
Published In
Neuro Oncology
Volume
22
Published Date
Start Page
277
End Page
277

PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS

Authors
Johnson, M; II, HJ; Lipp, E; Affronti, M; Desjardins, A; Bhattacharya, M; Friedman, H; Ashley, D; Peters, K; Randazzo, D
URI
https://scholars.duke.edu/individual/pub1467894
Source
wos-lite
Published In
Neuro Oncology
Volume
22
Published Date
Start Page
134
End Page
134

CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS

Authors
Finlay, J; Mynarek, M; Dhall, G; Mazewski, C; Grundy, R; Cohen, BH; Robinson, G; Ashley, D; Stanek, JR; Gajjar, A; Rutkowski, S
URI
https://scholars.duke.edu/individual/pub1473626
Source
wos-lite
Published In
Neuro Oncology
Volume
22
Published Date
Start Page
396
End Page
397

CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS

Authors
Peters, K; Lipp, E; Broadwater, G; II, HJ; Johnson, M; Randazzo, D; Desjardins, A; Friedman, H; Ashley, D; Affronti, M
MLA Citation
Peters, Katherine, et al. “CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS.” Neuro Oncology, vol. 22, 2020, pp. 137–137.
URI
https://scholars.duke.edu/individual/pub1467895
Source
wos-lite
Published In
Neuro Oncology
Volume
22
Published Date
Start Page
137
End Page
137

Cognitive Outcomes of Phase I Trial of Novel Metalloporphyrin Radioprotectant and Radiosensitizer in Newly Diagnosed High Grade Glioma Patients.

MASCC20-ABS-1534
Authors
Peters, KB; Kirkpatrick, J; Batinic-Haberle, I; Affronti, ML; Woodring, S; Iden, D; Lipp, ES; Healy, P; Herndon, JE; Boyd, K; Hahn, K; Spasojevic, I; Gad, S; Silberstein, D; Johnson, MO; Randazzo, D; Desjardins, A; Friedman, HS; Ashley, D; Crapo, J
MLA Citation
Peters, Katherine B., et al. “Cognitive Outcomes of Phase I Trial of Novel Metalloporphyrin Radioprotectant and Radiosensitizer in Newly Diagnosed High Grade Glioma Patients.Supportive Care in Cancer, Springer (part of Springer Nature), 2020.
URI
https://scholars.duke.edu/individual/pub1458678
Source
manual
Published In
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Published Date